Glaukos Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Glaukos (NYSE: GKOS) has announced its participation in two upcoming investor conferences: the William Blair 44th Annual Growth Stock Conference on June 5, 2024, at 1:40 p.m. ET in Chicago, and the Truist MedTech Conference on June 18, 2024, at 12:45 p.m. ET in Boston. Glaukos specializes in therapies for glaucoma, corneal disorders, and retinal diseases. Live and archived webcasts of these events will be available on the Glaukos website.

Positive

• Scheduled participation in high-profile investor conferences can increase visibility and investor interest.
• Engagement in these conferences may provide opportunities to discuss future growth plans and innovations.

Negative

• No new financial or clinical data disclosed in the announcement, providing immediate insight for investors.
• Potentially perceived as a routine update with no material impact on stock performance.

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences:

• William Blair 44^th Annual Growth Stock Conference on Wednesday, June 5, 2024, at 1:40 p.m. ET in Chicago, IL
• Truist MedTech Conference on Tuesday, June 18, 2024, at 12:45 p.m. ET in Boston, MA

A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528383262/en/

Chris Lewis

Vice President, Investor Relations & Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation

FAQ

When will Glaukos participate in the William Blair 44th Annual Growth Stock Conference?

Glaukos will participate on June 5, 2024, at 1:40 p.m. ET.

What date is Glaukos scheduled for the Truist MedTech Conference?

Glaukos is scheduled to participate on June 18, 2024, at 12:45 p.m. ET.

Where can I access the webcast for Glaukos' investor conferences?

Live and archived webcasts will be available in the Investors section of the Glaukos website.

What is the stock symbol for Glaukos ?

The stock symbol for Glaukos is GKOS.

What type of therapies does Glaukos specialize in?

Glaukos specializes in therapies for glaucoma, corneal disorders, and retinal diseases.